Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|July 1, 2001
- Pharmaceutical Technology-07-02-2001
- Volume 25
- Issue 7
25 Years of Change in the Parenteral Technology Field
Significant advances have shaped the past 25 years in the pharmaceutical industry, and the next 25 years will be no exception.
Advertisement
Articles in this issue
over 25 years ago
Musings on the Past 25 Yearsover 25 years ago
Reflections on Changes at FDAover 25 years ago
Deliver the Doseover 25 years ago
Middle-European Pharmaceutics in a Changing Worldover 25 years ago
The BCS: Where Do We Go From Here?over 25 years ago
From Inactive Ingredients to Pharmaceutical Excipientsover 25 years ago
Am I Going Backwards?over 25 years ago
The Filter Scene: Old and Newover 25 years ago
Catching Up with Expert SystemsAdvertisement
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement